ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
2024年4月3日 - 8:00PM
ADC Therapeutics SA (NYSE: ADCT) today announced that the Company
will host a virtual Research Investor Event on Tuesday, April 9,
2024, from 4:00 to 5:30 p.m. EDT. The event will feature
presentations from Ameet Mallik, Chief Executive Officer, and
Patrick van Berkel, PhD, Chief Scientific Officer, highlighting
recent updates and the Company’s novel exatecan-based antibody drug
conjugate platform. A live question and answer session will follow
the presentations.
To access the conference call, please register here. Registrants
will receive the dial-in number and unique PIN. It is recommended
that you join 10 minutes before the event, though you may
pre-register at any time. A live webcast of the call will be
available under “Events and Presentations” in the Investors section
of the ADC Therapeutics website at ir.adctherapeutics.com. The
archived webcast will be available for 30 days following the
call.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global
leader and pioneer in the field of antibody drug conjugates (ADCs).
The Company is advancing its proprietary ADC technology to
transform the treatment paradigm for patients with hematologic
malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab
tesirine-lpyl) received accelerated approval by the FDA and
conditional approval from the European Commission for the treatment
of relapsed or refractory diffuse large B-cell lymphoma after two
or more lines of systemic therapy. ZYNLONTA is also in development
in combination with other agents and in earlier lines of therapy.
In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in
ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and
has operations in London, the San Francisco Bay Area and New
Jersey. For more information, please visit
https://adctherapeutics.com/ and follow the Company on
LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. In some cases you can identify
forward-looking statements by terminology such as “may”, “will”,
“should”, “would”, “expect”, “intend”, “plan”, “anticipate”,
“believe”, “estimate”, “predict”, “potential”, “seem”, “seek”,
“future”, “continue”, or “appear” or the negative of these terms or
similar expressions, although not all forward-looking statements
contain these identifying words. Forward-looking statements are
subject to certain risks and uncertainties that can cause actual
results to differ materially from those described. Factors that may
cause such differences include, but are not limited to: the timing,
future success and results from the various ADCT research programs,
the success of the Company’s updated corporate strategy including
operating efficiencies, capital deployment and portfolio
prioritization; the Company’s ability to achieve the decrease in
total operating expenses for 2023 and 2024, the expected cash
runway into 4Q 2025, the effectiveness of the new commercial
go-to-market strategy, competition from new technologies, and the
Company’s ability to grow ZYNLONTA® revenue in the United States;
Swedish Orphan Biovitrum AB (Sobi®) ability to successfully
commercialize ZYNLONTA® in the European Economic Area and market
acceptance, adequate reimbursement coverage, and future revenue
from the same; approval by the NMPA of the BLA for ZYNLONTA® in
China submitted by Overland ADCT BioPharma and future revenue from
the same, our strategic partners’, including Mitsubishi Tanabe
Pharma Corporation, ability to obtain regulatory approval for
ZYNLONTA® in foreign jurisdictions, and the timing and amount of
future revenue and payments to us from such partnerships; the
impact, if any, from data reported by the University of Miami for
their IIT in FL; the timing and results of the Company’s or its
partners’ clinical trials including LOTIS 5 and 7, ADCT 601 and 602
as well as the Company’s early-stage pipeline research projects,
actions by the FDA or foreign regulatory authorities with respect
to the Company’s products or product candidates; projected revenue
and expenses; the Company’s indebtedness, including Healthcare
Royalty Management and Oaktree and Blue Owl facilities, and the
restrictions imposed on the Company’s activities by such
indebtedness, the ability to repay such indebtedness and the
significant cash required to service such indebtedness; and the
Company’s ability to obtain financial and other resources for its
research, development, clinical, and commercial activities.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the “Risk Factors”
section of the Company's Annual Report on Form 20-F and in the
Company's other periodic reports and filings with the Securities
and Exchange Commission. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or
prospects expressed in or implied by such forward-looking
statements. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in this
document. The Company undertakes no obligation to revise or update
these forward-looking statements to reflect events or circumstances
after the date of this press release, except as required by
law.
CONTACT:
Investors and MediaNicole RileyADC
TherapeuticsNicole.Riley@adctherapeutics.com+1 862-926-9040
ADC Therapeutics (NYSE:ADCT)
過去 株価チャート
から 5 2024 まで 6 2024
ADC Therapeutics (NYSE:ADCT)
過去 株価チャート
から 6 2023 まで 6 2024